FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3121234037> ?p ?o ?g. }

• W3121234037 endingPage "1050" @default.
• W3121234037 startingPage "1046" @default.
• W3121234037 abstract "Abstract Background Cobicistat, dolutegravir and rilpivirine are all modest inhibitors of proximal tubular creatinine secretion (IPTCrS) and hence a moderate and early non-progressive creatinine estimated glomerular filtration rate (Cr-eGFR) reduction has been observed in clinical trials. Data regarding the impact of combination of those drugs on Cr-eGFR, in the clinical practice, are scarcely known. Methods Changes in Cr-eGFR after starting darunavir/cobicistat alone or in combination with dolutegravir and/or rilpivirine were studied in a nationwide retrospective cohort study of consecutive HIV-infected patients initiating darunavir/cobicistat. The relationship between Cr-eGFR changes over time and the use of darunavir/cobicistat alone or darunavir/cobicistat plus dolutegravir and/or rilpivirine adjusted by different HIV patient’s characteristics, socio-demographics, HIV severity and use of tenofovir concomitant medication other than antiretrovirals was explored through univariate and multivariate analyses. Results The analysis included 725 patients. At 48 weeks, the combination of two or more IPTCrS (darunavir/cobicistat with rilpivirine and/or dolutegravir) was associated with higher decreases in Cr-eGFR [adjusted median difference (±SD) –3.5 ± 1.6 (95% CI –6.6 to –0.3), P = 0.047], and a decrease up to or higher than 15 mL/min/1.73 m2 was more frequent [adjusted OR 3.233 (95% CI 1.343–7.782), P = 0.009], with respect to darunavir/cobicistat alone. The Cr-eGFR changes between darunavir/cobicistat and darunavir/cobicistat with rilpivirine and/or dolutegravir showed more significant decreases in patients taking two or more IPTCrS at 12, 24 and 48 weeks. (ClinicalTrials.gov: NCT03042390). Conclusions Concomitant use of darunavir/cobicistat plus IPTCrS dolutegravir, rilpivirine, or both produced an additive effect in the expected Cr-eGFR decrease." @default.
• W3121234037 created "2021-02-01" @default.
• W3121234037 creator A5014887076 @default.
• W3121234037 creator A5025940626 @default.
• W3121234037 creator A5028013668 @default.
• W3121234037 creator A5029391761 @default.
• W3121234037 creator A5030312252 @default.
• W3121234037 creator A5059059064 @default.
• W3121234037 creator A5059398898 @default.
• W3121234037 creator A5060134820 @default.
• W3121234037 creator A5066358721 @default.
• W3121234037 creator A5066865065 @default.
• W3121234037 creator A5075175392 @default.
• W3121234037 creator A5076012773 @default.
• W3121234037 creator A5078695847 @default.
• W3121234037 creator A5079555852 @default.
• W3121234037 creator A5081538828 @default.
• W3121234037 creator A5090245488 @default.
• W3121234037 date "2021-01-27" @default.
• W3121234037 modified "2023-10-09" @default.
• W3121234037 title "Dynamics of creatinine estimated glomerular filtration rate using one or more antiretrovirals that inhibit creatinine tubular secretion" @default.
• W3121234037 cites W1983455184 @default.
• W3121234037 cites W2017404902 @default.
• W3121234037 cites W2033711468 @default.
• W3121234037 cites W2034122697 @default.
• W3121234037 cites W2139430929 @default.
• W3121234037 cites W2145467751 @default.
• W3121234037 cites W2397078747 @default.
• W3121234037 cites W2752494178 @default.
• W3121234037 cites W2753489952 @default.
• W3121234037 cites W2781681713 @default.
• W3121234037 cites W2793832384 @default.
• W3121234037 cites W2941953602 @default.
• W3121234037 cites W2963036706 @default.
• W3121234037 doi "https://doi.org/10.1093/jac/dkaa547" @default.
• W3121234037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33501995" @default.
• W3121234037 hasPublicationYear "2021" @default.
• W3121234037 type Work @default.
• W3121234037 sameAs 3121234037 @default.
• W3121234037 citedByCount "2" @default.
• W3121234037 countsByYear W31212340372021 @default.
• W3121234037 countsByYear W31212340372022 @default.
• W3121234037 crossrefType "journal-article" @default.
• W3121234037 hasAuthorship W3121234037A5014887076 @default.
• W3121234037 hasAuthorship W3121234037A5025940626 @default.
• W3121234037 hasAuthorship W3121234037A5028013668 @default.
• W3121234037 hasAuthorship W3121234037A5029391761 @default.
• W3121234037 hasAuthorship W3121234037A5030312252 @default.
• W3121234037 hasAuthorship W3121234037A5059059064 @default.
• W3121234037 hasAuthorship W3121234037A5059398898 @default.
• W3121234037 hasAuthorship W3121234037A5060134820 @default.
• W3121234037 hasAuthorship W3121234037A5066358721 @default.
• W3121234037 hasAuthorship W3121234037A5066865065 @default.
• W3121234037 hasAuthorship W3121234037A5075175392 @default.
• W3121234037 hasAuthorship W3121234037A5076012773 @default.
• W3121234037 hasAuthorship W3121234037A5078695847 @default.
• W3121234037 hasAuthorship W3121234037A5079555852 @default.
• W3121234037 hasAuthorship W3121234037A5081538828 @default.
• W3121234037 hasAuthorship W3121234037A5090245488 @default.
• W3121234037 hasConcept C126322002 @default.
• W3121234037 hasConcept C126894567 @default.
• W3121234037 hasConcept C142462285 @default.
• W3121234037 hasConcept C144301174 @default.
• W3121234037 hasConcept C159047783 @default.
• W3121234037 hasConcept C159641895 @default.
• W3121234037 hasConcept C2778723075 @default.
• W3121234037 hasConcept C2779182219 @default.
• W3121234037 hasConcept C2779298103 @default.
• W3121234037 hasConcept C2779502633 @default.
• W3121234037 hasConcept C2780306776 @default.
• W3121234037 hasConcept C2780524789 @default.
• W3121234037 hasConcept C2993143319 @default.
• W3121234037 hasConcept C3013748606 @default.
• W3121234037 hasConcept C38180746 @default.
• W3121234037 hasConcept C71924100 @default.
• W3121234037 hasConcept C98274493 @default.
• W3121234037 hasConceptScore W3121234037C126322002 @default.
• W3121234037 hasConceptScore W3121234037C126894567 @default.
• W3121234037 hasConceptScore W3121234037C142462285 @default.
• W3121234037 hasConceptScore W3121234037C144301174 @default.
• W3121234037 hasConceptScore W3121234037C159047783 @default.
• W3121234037 hasConceptScore W3121234037C159641895 @default.
• W3121234037 hasConceptScore W3121234037C2778723075 @default.
• W3121234037 hasConceptScore W3121234037C2779182219 @default.
• W3121234037 hasConceptScore W3121234037C2779298103 @default.
• W3121234037 hasConceptScore W3121234037C2779502633 @default.
• W3121234037 hasConceptScore W3121234037C2780306776 @default.
• W3121234037 hasConceptScore W3121234037C2780524789 @default.
• W3121234037 hasConceptScore W3121234037C2993143319 @default.
• W3121234037 hasConceptScore W3121234037C3013748606 @default.
• W3121234037 hasConceptScore W3121234037C38180746 @default.
• W3121234037 hasConceptScore W3121234037C71924100 @default.
• W3121234037 hasConceptScore W3121234037C98274493 @default.
• W3121234037 hasFunder F4320334923 @default.
• W3121234037 hasFunder F4320335322 @default.
• W3121234037 hasIssue "4" @default.
• W3121234037 hasLocation W31212340371 @default.
• W3121234037 hasOpenAccess W3121234037 @default.

• next